Investigating a new compound to prevent protein aggregation in Alzheimer's disease.
Investigations of the protein aggregation inhibitor NU-9 and its derivatives: mode of action and impact on Alzheimer’s disease and related dementias
['FUNDING_R01'] · NORTHWESTERN UNIVERSITY AT CHICAGO · NIH-10885308
This study is looking at a new compound called NU-9 to see if it can help improve brain health for people with Alzheimer's and similar conditions by reducing harmful protein buildup and supporting healthy brain cells.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | NORTHWESTERN UNIVERSITY AT CHICAGO (nih funded) |
| Locations | 1 site (CHICAGO, UNITED STATES) |
| Trial ID | NIH-10885308 on ClinicalTrials.gov |
What this research studies
This research focuses on a compound called NU-9, which has shown promise in improving the health of neurons affected by Alzheimer's disease and related dementias. The study aims to understand how NU-9 works to reduce protein aggregation, a key factor in neurodegeneration, and to explore its effects on cellular mechanisms that contribute to these diseases. By targeting common pathways that lead to neuronal death, the research seeks to develop broader treatment strategies that could benefit patients with various neurodegenerative conditions. Patients may be involved in trials to assess the effectiveness of NU-9 and its derivatives in improving their neurological health.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or related dementias, particularly those experiencing symptoms related to protein aggregation.
Not a fit: Patients with neurodegenerative diseases not related to protein aggregation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options that significantly improve the quality of life for patients with Alzheimer's disease and related dementias.
How similar studies have performed: Previous research has shown success with similar approaches targeting protein aggregation in neurodegenerative diseases, indicating potential for this novel compound.
Where this research is happening
CHICAGO, UNITED STATES
- NORTHWESTERN UNIVERSITY AT CHICAGO — CHICAGO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: OZDINLER, PEMBE HANDE — NORTHWESTERN UNIVERSITY AT CHICAGO
- Study coordinator: OZDINLER, PEMBE HANDE
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Alzheimer disease dementia, Alzheimer syndrome, Alzheimer's Disease, Alzheimer's disease and related dementia, Alzheimer's disease and related disorders